Aligning Regulatory Approach with Commercial Needs
CelLBxHealth plc is discontinuing the maintenance of its FDA establishment license and device listing for the Parsortix system to align with current commercial needs and strengthen cost discipline, as over 97% of platforms are used for research where the listing offers no commercial benefit. This strategic adjustment allows the company to reallocate resources towards revenue growth, customer support, and product development, while retaining the flexibility to reinstate the listing if advantageous. The decision has no impact on sales pipelines, market forecasts, customer support, or ongoing partnerships.
Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes
Guildford, UK and Plymouth Meeting, US - 13 February 2026 - CelLBxHealth plc (AIM:CLBX), a leader in circulating tumor cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces that it has decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix® system, which aligns its regulatory strategy with the Company's current operational and commercial priorities and strengthening cost discipline.
This decision reflects the Company's revised business model and customer usage patterns. More than 97% of Parsortix platforms in the field are deployed for in-house translational research and assay development activities, where an active device listing provides no commercial benefit. By streamlining these expenses, CelLBxHealth can reallocate resources to areas that directly support revenue growth, customer support, and product development.
Importantly, the Company retains the flexibility to reinstate the device listing at any time through payment of the applicable annual fees should commercial opportunities make it advantageous to do so.
This change has no impact on CelLBxHealth's sales pipeline, market forecasts, customer support, or ongoing partnerships.
Peter Collins CEO of CelLBxHealth commented:
"Our decision to discontinue the current FDA establishment license and device listing is a practical step that reflects how our customers are using the Parsortix platform today. With most platforms supporting translational research and assay development, maintaining this listing does not presently add commercial value. By optimizing our cost structure, we can invest more directly in revenue generation while retaining the option to reinstate the regulatory listing when it supports future revenue opportunities. We remain confident in our growth trajectory and excited about the expanding role of the Parsortix platform within the precision oncology market."
CelLBxHealth continues to focus on expanding its research, CRO and clinical laboratory collaborations, to advance LDT development programs, and strengthening its position as a leader in CTC solutions.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.